A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

J Thromb Thrombolysis. 2021 Apr;51(3):711-719. doi: 10.1007/s11239-020-02346-7. Epub 2020 Nov 28.

Abstract

In paediatric acute lymphoblastic leukaemia (ALL), focus has shifted towards preventing treatment-related complications, including venous thromboembolism, the cause of significant mortality and morbidity. To better understand thrombogenic mechanisms during induction treatment, we studied the number, origin and procoagulant activity of extracellular vesicles (EVs) and P-selectin level throughout the induction course in 24 paediatric patients. EVs were mainly of platelet origin. We observed a significant increase in EV number, in platelet EV number and P-selectin level throughout the induction course. There was a correlation between higher EV and platelet EV number, P-selectin level, higher platelet count and leucocyte count. We also observed a correlation between higher EV procoagulant activity and higher platelet count and leucocyte count and higher P-selectin level. Older age and T phenotype were associated with a higher EV procoagulant activity. Platelet EV generation may play a role in thrombogenic complications in ALL patients and could serve as a biomarker to identify patients with a high risk of thrombosis. As a marker of platelet activation, P-selectin may be another relevant marker with the advantage of being easier to analyse in clinical practice.

Keywords: Acute lymphoblastic leukaemia; Extracellular vesicles; Platelets; Venous thromboembolism.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Asparaginase / therapeutic use*
  • Biomarkers / blood
  • Blood Coagulation / drug effects
  • Blood Coagulation / physiology
  • Blood Platelets / metabolism
  • Blood Platelets / pathology
  • Child
  • Correlation of Data
  • Extracellular Vesicles* / metabolism
  • Extracellular Vesicles* / pathology
  • Female
  • Humans
  • Induction Chemotherapy* / adverse effects
  • Induction Chemotherapy* / methods
  • Leukocyte Count / methods
  • Leukocyte Count / statistics & numerical data
  • Male
  • P-Selectin / blood*
  • Pilot Projects
  • Platelet Activation / drug effects
  • Platelet Count* / methods
  • Platelet Count* / statistics & numerical data
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / blood
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Venous Thromboembolism* / blood
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / etiology

Substances

  • Antineoplastic Agents
  • Biomarkers
  • P-Selectin
  • Asparaginase